Introduction
In late 2019, the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also referred to as coronavirus illness 2019 (COVID-19), began to unfold around the globe, turning into a worldwide emergency and resulting in a worldwide well being disaster, which utterly revolutionized each side of human life.1–3 A number of methods had been adopted to restrict the spreading of the an infection resembling testing and phone tracing, quarantine and isolation, use of face masks, social distancing, lockdowns, journey restrictions, public well being messages, hygiene measures, worldwide cooperation, and vaccination marketing campaign.4–6
Of those, vaccines had been crucial measures to scale back the transmission of the virus and the severity of the an infection, as a way to overcome the pandemic.7 At the moment, 4 vaccines have been licensed by the European Medicines Company (EMA), with two totally different mechanisms of motion: viral-vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2.) and mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273).7 Furthermore, a number of vaccines have been licensed in different international locations resembling “Sputnik V” (Gamaleya Analysis Institute), “Convidecia” (CanSino Biologics), and “CoronaVac” (Sinovac).7 Nevertheless, additionally vaccination marketing campaign was a worldwide problem as a result of a number of considerations raised by vaccines themselves.8–10 To begin with, there have been logistic considerations (vaccine provide and distribution, manufacturing capability, equitable entry, infrastructure and healthcare workforce, logistical challenges, public communication, authorized and regulatory challenges, and many others.).8,9 Secondly, vaccination marketing campaign was additionally restricted by vaccine hesitancy, usually as a result of misinformation and distrust of vaccination associated to the rapidity of manufacturing of vaccines and the mechanism of motion, notably mRNA based mostly.8,9 Fortuitously, the preliminary doubts about vaccines had been overcome in addition to logistic considerations had been solved.8,9,11 On consequence, vaccination marketing campaign was successful, displaying to be environment friendly in controlling and stopping the COVID-19 pandemic, lowering the chance of illness development, hospitalization, and mortality.8,9
On this situation, monitoring and addressing vaccine-related antagonistic occasions (AEs) have been important for sustaining public confidence.12,13 As regards the dermatological discipline, with the growing variety of vaccines administered, numerous cutaneous reactions have been reported, making dermatologists key gamers of their recognition and therapy.14–20 Notably, a number of cutaneous ailments (eg, psoriasis, lichen planus, hidradenitis suppurativa, bullous ailments, and many others.) and cutaneous findings (eg, maculopapular, urticarial, vesicular rashes, and many others.) have been reported.21–23 Nevertheless, the scientific significance of those reactions, and the attainable pathogenetic mechanisms, remains to be unknown, as nicely correctly famous that within the majority of circumstances, these reactions had been self-resolving or restricted to some days.21–23 Of be aware, additionally viral reactivations have been described following COVID-19 vaccination. Amongst these, varicella zoster virus (VZV) reactivation has been collected. VZV is a posh medical situation that will contain infectiology, dermatology, and neurology, making its therapy difficult.24–26 Whereas varicella is brought on by acute viremia, herpes zoster (HZ) is brought on by viral reactivation, usually involving a single dermatome and presenting as burning or ache adopted by a cutaneous eruption with a number of umbilicated and painful vesicles.27 The precise triggers for reactivation aren’t absolutely understood however might contain a weakened immune system, getting older, or stress.27 Furthermore, HZ an infection could also be difficult by postherpetic neuralgia, secondary bacterial an infection, or ophthalmic problems.27 Thus, an early analysis and an correct therapy are necessary.27 On this context, we carried out a assessment of the present literature investigating circumstances HZ following COVID-19 vaccination with the goal of understanding the attainable causal correlation and underlying pathogenetic mechanisms to supply clinicians a large perspective on VZV reactivation and COVID-19 vaccines.
Supplies and Strategies
For this assessment manuscript, a complete literature search was carried out through the use of a number of databases (Embase, MEDLINE, EBSCO, PubMed, Google Scholar, and the Cochrane Pores and skin), up till September 19, 2023. The next phrases had been searched and matched to seek out related manuscripts: “COVID-19”, “SARS-Coronavirus-2”, “SARS-CoV-2”; “cutaneous illness”, “cutaneous reactions”, “antagonistic occasions”, “BNT162b2”, “unwanted side effects”, “mRNA”, “AZD1222”, “viral-vector”, “mRNA-1273”, “Johnson & Johnson”, “Pfizer/BioNTech”, “Moderna”, “Ad26.COV2.S”, “AstraZeneca”, “vaccine”, “vaccination”, “efficacy”, “security”, “herpes zoster”. The Most popular Reporting Objects for Systematic critiques and Meta-analyses (PRISMA) pointers had been adopted to level out related information from the screened and analyzed articles.28 Furthermore, solely English language manuscripts had been thought-about. Moreover, the abstracts and the texts of designated articles had been reviewed to refine the analysis in addition to references had been additionally thought-about to keep away from that some manuscripts might be missed. Exclusion standards embody: non-English manuscripts, article relating to different viral reactivations or non-involving vaccines authorized by EMA. This manuscript is predicated on beforehand carried out research and doesn’t include any research with human or animals members carried out by any of the authors.
Outcomes
A complete of 76 data had been discovered from the investigated databases. Nevertheless, solely 72 manuscripts had been assessed for eligibility, since duplicate manuscripts and articles non-respecting examine had been excluded. Lastly, 31 manuscripts had been chosen on the finish of the literature analysis for our assessment.29–60
The outcomes have been summarized in Desk 1.
|
Desk 1 Varicella Zoster Virus Reactivation After COVID-19 Vaccine |
Globally, 4555 circumstances of HZ following COVID-19 vaccinations had been discovered. Amongst these, the biggest variety of circumstances has been reported by Florea et al in a cohort examine investigating the affiliation between mRNA COVID-19 vaccination and subsequent HZ improvement inside 90 days from vaccination.29 Cohort included: mRNA-1273 recipients (n = 1.052.362), BNT162b2 recipients (n = 1.055.461), and comparators (n = 1.020.334).29 The authors confirmed and adjusted hazard ratio (aHR) for HZ as much as 90 days following the second dose of mRNA-1273 and BNT162b2 of 1.14 (1.05–1.24) and 1.12 (1.03–1.22), respectively.29 Furthermore, an aHR of 1.18 (1.06–1.33) and 1.15 (1.02–1.29) was present in sufferers aged ≥50 years after the second dose of mRNA-1273 and BNT162b2 vaccine as in contrast with unvaccinated topics.29 In conclusion, the authors prompt an elevated threat of HZ following COVID-19 vaccination, particularly in sufferers aged ≥50 years with out historical past of zoster vaccination.29
Equally, Barda et al assessed an elevated threat of VZV reactivation following COVID-19 vaccination with BNT162b2 of their cohort examine involving 884,828 topics.30 Amongst these, 283 circumstances of HZ had been collected, suggesting a constructive correlation between VZV reactivation and vaccination (threat ratio, 1.43; 95% CI, 1.20 to 1.73; threat distinction, 15.8 occasions per 100,000 individuals; 95% CI, 8.2 to 24.2).30
Quite the opposite, Birabaharan et al reported the outcomes a cohort examine enrolling 1,306,434 sufferers receiving at the very least one dose of mRNA-based COVID-19 vaccine.41 Of those, 1.228 (0.1%) reported VZV reactivation inside most of 28 days after vaccine. However, a statistically vital affiliation between HZ and COVID-19 vaccination was not discovered.41 On consequence, the authors acknowledged that COVID-19 vaccination was not related to an elevated threat of HZ.41 The principle limitation of the examine was the absence of the specification of the dose and kind of mRNA vaccine.41 In keeping with Birabaharan et al, additionally Akpandak et al confirmed that there was not an elevated threat of VZV following COVID-19 vaccination of their cohort of 1,959,157 people.52 Certainly, solely 45 circumstances had been reported, permitting the authors to conclude that there was not an elevated threat of HZ following vaccination with BNT162b2 (IRR = 0.90, 95% CI: 0.49–1.69, p = 0.74), mRNA-1273 (IRR = 0.74, 95% CI: 0.36–1.54, p = 0.42), or Ad26.COV2.S (IRR = 0.50, 95% CI: 0.07–2.56, p = 0.42).52
Globally, the remaining circumstances of HZ improvement following COVID-19 vaccination had been restricted to case collection and case studies. Amongst these, it ought to be identified 6 circumstances of HZ in sufferers with autoimmune inflammatory rheumatic ailments,31 3 topics with VZV meningitis difficult by enhancing nodular leptomeningeal lesions of the spinal twine and VZV ophthalmicus of the cornea and eyelid, respectively,38 and a case of VZV reactivation in a affected person beforehand vaccinated for VZV.53
Globally, the kind of COVID-19 vaccination related to HZ improvement was described just for 3282 out of 4555 topics (72.1%), with BNT162b2 as the most typical (n = 1711), adopted by mRNA-1273 (n = 1538), and Ad26.COV2 (n = 33). Lastly, the time between vaccination and VZV improvement ranged from 1 to 90 days.
Dialogue
COVID-19 pandemic interval strongly affected every day routine. Dermatological scientific follow was strongly pressured to undertake methods to distinction the COVID-19 diffusion as a way to permit sufferers the continuity of care.61–64 As regards the dermatological follow, dermatologists performed a key position throughout the pandemic making attainable to permit the continuity of take care of sufferers affected by persistent issues requiring numerous therapy resembling biologics,65–71 in addition to the administration of pores and skin cancers.72–74
Globally, among the many a number of measures adopted to include COVID-19 an infection,75 vaccination was crucial. The Herpesviridae household is a big household of double-stranded DNA viruses that infect a variety of animals, together with people, characterised by their means to ascertain latent infections, which implies they’ll stay dormant within the host’s cells for prolonged durations and reactivate later.76–78 Three subfamilies could be distinguished: alphaherpesvirinae (herpes simplex virus kind 1 and herpes simplex virus kind 2, which trigger oral and genital herpes, in addition to varicella-zoster virus), betaherpesvirinae (cytomegalovirus, human herpesvirus 6, and human herpesvirus 7 (HHV-7)), gammaherpesvirinae (Epstein–Barr virus and Kaposi’s sarcoma-associated herpesvirus). Specifically, alphaherpesvirinae establishes latent infections in neurons, whereas betaherpesvirinae and gammaherpesvirinae set up latent infections within the immune system and in lymphocytes and epithelial cells, respectively.76–78 These viruses may cause a variety of ailments, from gentle chilly sores to extreme and probably life-threatening circumstances, relying on the precise virus and the host’s immune standing.76–78 Reactivation of herpesviruses (Epstein–Barr virus, cytomegalovirus and herpes simplex virus) following COVID-19 vaccination have been reported by a number of case studies. Nevertheless, VZV reactivation is the most typical. On this context, we carried out a assessment of the present literature to find out the correlation between the COVID-19 vaccination and VZV. Of curiosity, VZV reactivation was additionally reported following COVID-19 an infection.79
In our assessment, a complete of 31 manuscripts had been collected, reporting 4555 circumstances of HZ improvement following COVID-19 vaccination. Specifically, BNT162b2 was reported as the most typical kind of vaccine related to VZV reactivation, adopted by mRNA-1273 and Ad26.COV2. Nevertheless, it ought to be acknowledged that BNT162b2 is the most typical kind of vaccine administered. Lastly, the time between vaccination and VZV improvement ranged from 1 to 90 days. Of curiosity, circumstances of HZ have been described following each doses of vaccinations in addition to each varieties of mechanism of motion (mRNA-based or viral-vector based mostly) suggesting that the attainable pathogenetic mechanisms are unbiased from the mechanism of motion of vaccine. Globally, age, weakened immune system, stress, sure medical circumstances, damage or trauma, are thought-about as attainable threat elements. In principle, these circumstances might result in the reactivation of VZV.80–85 As regards COVID-19 vaccination and HZ, the attainable pathogenetic mechanism could also be discover within the immune imbalance associated to the vaccination.80–85 Certainly, vaccine causes CD8+ T cells discount, elevated NF-κB signaling, improve in traditional monocyte contents, and decreased kind I interferon responses, main the immune system in a weak state.80–85 Specifically, kind I IFN receptor signaling in CD8+ T cells performs a necessary position in regulating reminiscence cell response to viral an infection and blockage of reactivation.80–85 On consequence, the alteration of this method associated to COVID-19 vaccination could also be the reason for VZV reactivation.80–85 To summarize, circumstances of VZV reactivation have been reported additionally following different vaccines (resembling influenza, diphtheria, tuberculosis, poliomyelitis, and many others.).80–86 It’s attainable that in predisposed people, immune dysregulations induced by vaccines might result in viral reactivation, much like the phenomenon of “immune reconstitution inflammatory syndrome” noticed throughout HIV therapy.80–85 The stimulation of the immune response and its polarization in direction of a particular T-cell response in opposition to a selected infectious agent (eg, a vaccine) might briefly compromise the T-cell-mediated management of latent infections like VZV, HSV, HHV-6, and HHV-7, resulting in viral reactivation.80–85 Nevertheless, the precise pathogenetic mechanism stays unknown and additional research are wanted.
Furthermore, it ought to be acknowledged that circumstances of HZ following vaccination are uncommon, and solely few difficult circumstances have been described, in addition to the security of vaccination has been reported additionally in sufferers present process biologics.87–90 Thus, extra research are wanted to determine attainable threat elements, which can improve the chance of VZV following COVID-19 vaccination in addition to the protecting position of VZV vaccine as a way to determine “at-risk” sufferers. Definitely, the potential for HZ following vaccination ought to be thought-about as a way to early acknowledge and deal with this illness.
Strengths and Limitations
The principle strengths of our work had been the PRISMA strategies for the literature analysis and the quantity and high quality of investigated articles. Certainly, our examine affords a complete overview of the revealed literature and highlights the out there information with rigorous high quality evaluation.
Limitations of the examine must also be mentioned. To begin with, regardless of all the reported circumstances which were collected in our assessment, the variety of sufferers is insufficient for definitely assessing the correlation between vaccines and VZV reactivation. Second, scientific trials or comparability between vaccinated and non-vaccinated members are missing. Moreover, the causal temporal correlation between COVID-19 vaccination and viral response can’t be dominated out in many of the circumstances. As well as, a number of viral reactivations associated to COVID-19 vaccines haven’t been described in literature as a result of they had been gentle and/or sufferers didn’t search medical recommendation, resulting in an underestimation of the epidemiological worth of our work. Furthermore, our assumptions, particularly within the dialogue, have to be taken merely as solutions and never as particular proposals, as our work has not had the help of meta-analysis, which can permit our outcomes to be generalized. Lastly, a number of cutaneous reactions associated to COVID-19 vaccination weren’t thought-about in our assessment.91,92
Conclusions
COVID-19 vaccination marketing campaign was a worldwide success. Nevertheless, with the elevating variety of vaccinated people, a number of cutaneous reactions have been reported, which regularly weren’t collected in scientific trials. Amongst these, viral reactivations have been described. In our assessment, we targeted the eye to VZV reactivation following COVID-19 vaccination, which is the most typical described viral reactivation. Fortuitously, the proportion of HZ improvement is extraordinarily low if in contrast with the variety of vaccines administered in addition to an elevated threat of VZV reactivation following vaccination can’t be statistically demonstrated. In our opinion, clinicians ought to bear in mind the potential for HZ improvement following vaccination to supply sufferers a customized strategy.93,94 Furthermore, extra research are wanted to determine “at-risk” sufferers and undertake preventative measures. Definitely, vaccines shouldn’t be discouraged.
Disclosure
The authors report no conflicts of curiosity on this work.
References
1. Sharma A, Ahmad Farouk I, Lal SK. COVID-19: a assessment on the novel coronavirus illness evolution, transmission, detection, management and prevention. Viruses. 2021;13(2):202. doi:10.3390/v13020202
2. Hadj Hassine I. Covid-19 vaccines and variants of concern: a assessment. Rev Med Virol. 2022;32(4):e2313. doi:10.1002/rmv.2313
3. Smith DRM, Chervet S, Pinettes T, et al. How have mathematical fashions contributed to understanding the transmission and management of SARS-CoV-2 in healthcare settings? A scientific search and assessment. J Hosp Infect. 2023;141:132–141. doi:10.1016/j.jhin.2023.07.028
4. Salian VS, Wright JA, Vedell PT, et al. COVID-19 transmission, present therapy, and future therapeutic methods. Mol Pharm. 2021;18(3):754–771. doi:10.1021/acs.molpharmaceut.0c00608
5. Khan M, Adil SF, Alkhathlan HZ, et al. COVID-19: a worldwide problem with outdated historical past, epidemiology and progress thus far. Molecules. 2020;26(1):39. doi:10.3390/molecules26010039
6. Ruggiero A, Martora F, Fabbrocini G, et al. The position of teledermatology throughout the COVID-19 pandemic: a story assessment. Clin Cosmet Investig Dermatol. 2022;15:2785–2793. doi:10.2147/CCID.S377029
7. Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. COVID-19 vaccines mix-and-match: the idea, the efficacy and the doubts. J Med Virol. 2022;94(4):1294–1299. doi:10.1002/jmv.27463
8. Troiano G, Nardi A. Vaccine hesitancy within the period of COVID-19. Public Well being. 2021;194:245–251. doi:10.1016/j.puhe.2021.02.025
9. Joshi A, Kaur M, Kaur R, Grover A, Nash D, El-Mohandes A. Predictors of COVID-19 vaccine acceptance, intention, and hesitancy: a scoping assessment. Entrance Public Heal. 2021;9:698111. doi:10.3389/fpubh.2021.698111
10. Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Pores and skin response after SARS-CoV-2 vaccines Reply to “cutaneous antagonistic reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre expertise”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
11. Potestio L, Fabbrocini G, D’Agostino M, Piscitelli I, Martora F. Cutaneous reactions following COVID-19 vaccination: the proof says “much less worry”. J Cosmet Dermatol. 2023;22(1):28–29. doi:10.1111/jocd.15533
12. Potestio L, Villani A, Fabbrocini G, Martora F. Cutaneous reactions following booster dose of COVID-19 mRNA vaccination: what we should always know? J Cosmet Dermatol. 2022;21(11):5339–5340. doi:10.1111/jocd.15331
13. Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Evaluating COVID-19 vaccines for his or her traits, efficacy and effectiveness in opposition to SARS-CoV-2 and variants of concern: a story assessment. Clin Microbiol Infect. 2022;28(2):202–221. doi:10.1016/j.cmi.2021.10.005
14. De Lucia M, Potestio L, Costanzo L, Fabbrocini G, Gallo L. Scabies outbreak throughout COVID-19: an Italian expertise. Int J Dermatol. 2021;60(10):1307–1308. doi:10.1111/ijd.15809
15. Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case collection. Dermatol Ther. 2022;35(2):e15225. doi:10.1111/dth.15225
16. Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful gizmo additionally after COVID-19 period? J Cosmet Dermatol. 2022;21(6):2309–2310. doi:10.1111/jocd.14938
17. Maronese CA, Caproni M, Moltrasio C, et al. Bullous pemphigoid related to COVID-19 vaccines: an Italian multicentre examine. Entrance Med. 2022;9:841506. doi:10.3389/fmed.2022.841506
18. Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 trigger atypical types of pityriasis rosea refractory to traditional therapies? J Med Virol. 2022;94(4):1292–1293. doi:10.1002/jmv.27535
19. Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: scientific and laboratory findings with a selected emphasis on differential analysis. J Allergy Clin Immunol. 2022;149(4):1137–1149. doi:10.1016/j.jaci.2022.02.007
20. Maronese CA, Zelin E, Avallone G, et al. Cutaneous vasculitis and vasculopathy within the period of COVID-19 pandemic. Entrance Med. 2022;9:996288. doi:10.3389/fmed.2022.996288
21. Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory pores and skin ailments. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
22. Wack S, Patton T, Ferris LK. COVID-19 vaccine security and efficacy in sufferers with immune-mediated inflammatory illness: assessment of accessible proof. J Am Acad Dermatol. 2021;85(5):1274–1284. doi:10.1016/j.jaad.2021.07.054
23. Martora F, Battista T, Marasca C, Genco L, Fabbrocini G, Potestio L. Cutaneous reactions following COVID-19 vaccination: a assessment of the present literature. Clin Cosmet Investig Dermatol. 2022;15:2369–2382. doi:10.2147/CCID.S388245
24. van Dam CS, Lede I, Schaar J, Al-Dulaimy M, Rösken R, Smits M. Herpes zoster after COVID vaccination. Int J Infect Dis. 2021;111:169–171. doi:10.1016/j.ijid.2021.08.048
25. Akpandak I, Miller DC, Solar Y, Arnold BF, Kelly JD, Acharya NR. Evaluation of herpes zoster threat amongst recipients of COVID-19 vaccine. JAMA Netw open. 2022;5(11):e2242240. doi:10.1001/jamanetworkopen.2022.42240
26. Eid E, Abdullah L, Kurban M, Abbas O. Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. 2021;93(9):5231–5232. doi:10.1002/jmv.27036
27. Patil A, Goldust M, Wollina U. Herpes zoster: a assessment of scientific manifestations and administration. Viruses. 2022;14(2). doi:10.3390/v14020192
28. Web page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 assertion: an up to date guideline for reporting systematic critiques. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
29. Florea A, Wu J, Qian L, et al. Danger of herpes zoster following mRNA COVID-19 vaccine administration. Knowledgeable Rev Vaccines. 2023;22(1):643–649. doi:10.1080/14760584.2023.2232451
30. Barda N, Dagan N, Ben-Shlomo Y, et al. Security of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–1090. doi:10.1056/NEJMoa2110475
31. Monastirli A, Pasmatzi E, Badavanis G, Panagiotopoulou G, Apostolidou A, Tsambaos D. Herpes Zoster after mRNA COVID-19 vaccination: a case collection. Skinmed. 2022;20(4):284–288.
32. Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines. 2021;9(6):572. doi:10.3390/vaccines9060572
33. Furer V, Eviatar T, Zisman D, et al. Immunogenicity and security of the BNT162b2 mRNA COVID-19 vaccine in grownup sufferers with autoimmune inflammatory rheumatic ailments and within the common inhabitants: a multicentre examine. Ann Rheum Dis. 2021;80(10):1330–1338. doi:10.1136/annrheumdis-2021-220647
34. Rodríguez-Jiménez P, Chicharro P, Cabrera LM, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 circumstances. JAAD Case Rep. 2021;12:58–59. doi:10.1016/j.jdcr.2021.04.014
35. Alpalhão M, Filipe P. Herpes Zoster following SARS-CoV-2 vaccination – A collection of 4 circumstances. J Eur Acad Dermatol Venereol. 2021;35(11):e750–e752. doi:10.1111/jdv.17555
36. Chiu HH, Wei KC, Chen A, Wang WH. Herpes zoster following COVID-19 vaccine: a report of three circumstances. QJM. 2021;114(7):531–532. doi:10.1093/qjmed/hcab208
37. Jiang ZH, Wong LS, Lee CH, Hsu TJ, Yu YH. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. Indian J Dermatol Venereol Leprol. 2022;88(3):445. doi:10.25259/IJDVL_819_2021
38. Lazzaro DR, Ramachandran R, Cohen E, Galetta SL. Covid-19 vaccination and attainable hyperlink to Herpes zoster. Am J Ophthalmol Case Rep. 2022;25:101359. doi:10.1016/j.ajoc.2022.101359
39. Mohta A, Arora A, Srinivasa R, Mehta RD. Recurrent herpes zoster after COVID-19 vaccination in sufferers with persistent urticaria being handled with cyclosporine-A report of three circumstances. J Cosmet Dermatol. 2021;20(11):3384–3386. doi:10.1111/jocd.14437
40. Vastarella M, Picone V, Martora F, Fabbrocini G. Herpes zoster after ChAdOx1 nCoV-19 vaccine: a case collection. J Eur Acad Dermatol Venereol. 2021;35(12):e845–e846. doi:10.1111/jdv.17576
41. Birabaharan M, Kaelber DC, Karris MY. Danger of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort examine. J Am Acad Dermatol. 2022;87(3):649–651. doi:10.1016/j.jaad.2021.11.025
42. Özdemir AK, Kayhan S, Çakmak SK. Herpes zoster after inactivated SARS-CoV-2 vaccine in two wholesome younger adults. J Eur Acad Dermatol Venereol. 2021;35(12):e846–e847. doi:10.1111/jdv.17577
43. Palanivel JA. Herpes zoster after COVID-19 vaccination-Can the vaccine reactivate latent zoster virus? J Cosmet Dermatol. 2021;20(11):3376–3377. doi:10.1111/jocd.14470
44. Rehman O, Arya SK, Jha UP, Nayyar S, Goel I. Herpes zoster ophthalmicus after COVID-19 vaccination: probability incidence or extra? Cornea. 2022;41(2):254–256. doi:10.1097/ICO.0000000000002881
45. Toscani I, Troiani A, Citterio C, Rocca G, Cavanna L. Herpes zoster following COVID-19 vaccination in long-term breast most cancers survivors. Cureus. 2021;13(10):e18418. doi:10.7759/cureus.18418
46. Aksu SB, Öztürk GZ. A uncommon case of shingles after COVID-19 vaccine: is it a attainable antagonistic impact? Clin Exp Vaccine Res. 2021;10(2):198–201. doi:10.7774/cevr.2021.10.2.198
47. Ardalan M, Moslemi H, Shafiei S, Tabrizi R, Moselmi M. Herpes-like pores and skin lesion after AstraZeneca vaccination for COVID-19: a case report. Clin Case Rep. 2021;9(10):e04883. doi:10.1002/ccr3.4883
48. Channa L, Torre Okay, Rothe M. Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination. JAAD Case Rep. 2021;15:60–61. doi:10.1016/j.jdcr.2021.05.042
49. David E, Landriscina A. Herpes Zoster following COVID-19 vaccination. J Medicine Dermatol. 2021;20(8):898–900. doi:10.36849/JDD.6146
50. Tessas I, Kluger N. Ipsilateral herpes zoster after the primary dose of BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(10):e620–e622. doi:10.1111/jdv.17422
51. Tripathy DM, Kumar S, Saraswat N, Goel S, Ranjan E. Postherpetic granulomatous dermatitis and herpes zoster necroticans triggered by Covid-19 vaccination. Dermatol Ther. 2022;35(10):e15707. doi:10.1111/dth.15707
52. Akpandak I, Sechrist SJ, Miller DC, et al. Danger of herpes zoster ophthalmicus after COVID-19 vaccination in a big US healthcare claims database. Am J Ophthalmol. 2023. doi:10.1016/j.ajo.2023.07.004
53. Vallianou NG, Tsilingiris D, Karampela I, Liu J, Dalamaga M. Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster grownup: a two-vaccine associated occasion? Metab Open. 2022;13:100171. doi:10.1016/j.metop.2022.100171
54. You IC, Ahn M, Cho NC. A case report of herpes zoster ophthalmicus and meningitis after COVID-19 vaccination. J Korean Med Sci. 2022;37(20):e165. doi:10.3346/jkms.2022.37.e165
55. Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide examine of 405 circumstances. Br J Dermatol. 2022;186(1):142–152. doi:10.1111/bjd.20639
56. Fathy RA, McMahon DE, Lee C, et al. Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a assessment of 40 circumstances in an Worldwide Dermatology Registry. J Eur Acad Dermatol Venereol. 2022;36(1):e6–e9. doi:10.1111/jdv.17646
57. Naoum C, Hartmann M. Herpes zoster reactivation after COVID-19 vaccination – A retrospective case collection of twenty-two sufferers. Int J Dermatol. 2022;61(5):628–629. doi:10.1111/ijd.16116
58. Lee C, Cotter D, Basa J, Greenberg HL. 20 Publish-COVID-19 vaccine-related shingles circumstances seen on the Las Vegas Dermatology clinic and despatched to us through social media. J Cosmet Dermatol. 2021;20(7):1960–1964. doi:10.1111/jocd.14210
59. Lee JH, Kim YY, Heo HJ, Park JH, Cho HG, Kim G. Herpes zoster after COVID-19 vaccination, side of ache medication: a retrospective, single-center examine. Anesth ache Med. 2023;18(1):57–64. doi:10.17085/apm.22207
60. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based examine of 414 circumstances. J Am Acad Dermatol. 2021;85(1):46–55. doi:10.1016/j.jaad.2021.03.092
61. Ruggiero A, Martora F, Picone V, et al. The affect of COVID-19 an infection on sufferers with psoriasis handled with biologics: an Italian expertise. Clin Exp Dermatol. 2022;47(12):2280–2282. doi:10.1111/ced.15336
62. Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis sufferers present process therapy with biologics. Clin Exp Dermatol. 2022;47(12):2310–2312. doi:10.1111/ced.15395
63. Martora F, Martora L, Fabbrocini G, Marasca C. A case of pemphigus vulgaris and hidradenitis suppurativa: might systemic steroids be thought-about in the usual administration of hidradenitis suppurativa? Ski Appendage Disord. 2022;8(3):265–268. doi:10.1159/000521712
64. Martora F, Fabbrocini G, Nappa P, Megna M. Influence of the COVID-19 pandemic on hospital admissions of sufferers with uncommon ailments: an expertise of a Southern Italy referral heart. Int J Dermatol. 2022;61(7):e237–e238. doi:10.1111/ijd.16236
65. Megna M, Camela E, Battista T, et al. Efficacy and security of biologics and small molecules for psoriasis in pediatric and geriatric populations. Half I: deal with pediatric sufferers. Knowledgeable Opin Drug Saf. 2023:1–17. doi:10.1080/14740338.2023.2173170
66. Megna M, Camela E, Battista T, et al. Efficacy and security of biologics and small molecules for psoriasis in pediatric and geriatric populations. Half II: deal with aged sufferers. Knowledgeable Opin Drug Saf. 2023:1–16. doi:10.1080/14740338.2023.2173171
67. Martora F, Megna M, Battista T, et al. Adalimumab, ustekinumab, and secukinumab within the administration of hidradenitis suppurativa: a assessment of the real-life expertise. Clin Cosmet Investig Dermatol. 2023;16:135–148. doi:10.2147/CCID.S391356
68. Napolitano M, Maffei M, Patruno C, et al. Dupilumab effectiveness for the therapy of sufferers with concomitant atopic dermatitis and persistent rhinosinusitis with nasal polyposis. Dermatol Ther. 2021;34(6):e15120. doi:10.1111/dth.15120
69. Patruno C, Potestio L, Napolitano M. Scientific phenotypes of grownup atopic dermatitis and associated therapies. Curr Opin Allergy Clin Immunol. 2022;22(4):242–249. doi:10.1097/ACI.0000000000000837
70. Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the therapy of average to extreme psoriasis: outcomes from a single heart preliminary real-life examine. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
71. Patruno C, Potestio L, Scalvenzi M, et al. Dupilumab for the therapy of grownup atopic dermatitis in particular populations. J Dermatolog Deal with. 2022:1–6. doi:10.1080/09546634.2022.2102121
72. Villani A, Potestio L, Fabbrocini G, Scalvenzi M. New rising therapy choices for superior basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi:10.1007/s12325-022-02044-1
73. Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: pores and skin cancer-diagnosis, prevention, and therapy. Crit Rev Eukaryot Gene Expr. 2020;30(4):291–297. doi:10.1615/CritRevEukaryotGeneExpr.2020028454
74. Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the therapy of superior cutaneous squamous cell carcinoma. Knowledgeable Opin Drug Saf. 2022;21(1):21–29. doi:10.1080/14740338.2022.1993819
75. Marasca C, Annunziata MC, Camela E, et al. Teledermatology and inflammatory pores and skin circumstances throughout COVID-19 period: new views and functions. J Clin Med. 2022;11(6):1511. doi:10.3390/jcm11061511
76. Roizmann B, Desrosiers RC, Fleckenstein B, Lopez C, Minson AC, Studdert MJ. The household herpesviridae: an replace. The Herpesvirus Examine Group of the Worldwide Committee on Taxonomy of Viruses. Arch Virol. 1992;123(3–4):425–449. doi:10.1007/BF01317276
77. Kukhanova MK, Korovina AN, Kochetkov SN. Human herpes simplex virus: life cycle and improvement of inhibitors. Biochemistry. 2014;79(13):1635–1652. doi:10.1134/S0006297914130124
78. Carneiro VC, de S, Pereira JG, de Paula VS. Household Herpesviridae and neuroinfections: present standing and analysis in progress. Mem Inst Oswaldo Cruz. 2022;117:e220200. doi:10.1590/0074-02760220200
79. Brambilla L, Maronese CA, Tourlaki A, Veraldi S. Herpes zoster following COVID-19: a report of three circumstances. Eur J Dermatol. 2020;30(6):754–756. doi:10.1684/ejd.2020.3924
80. Shafiee A, Amini MJ, Arabzadeh Bahri R, et al. Herpesviruses reactivation following COVID-19 vaccination: a scientific assessment and meta-analysis. Eur J Med Res. 2023;28(1):278. doi:10.1186/s40001-023-01238-9
81. Stoeger T, Adler H. “Novel” triggers of herpesvirus reactivation and their potential well being relevance. Entrance Microbiol. 2018;9:3207. doi:10.3389/fmicb.2018.03207
82. Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the position of G-quadruplexes, exosomes, and MicroRNAs. Meals Chem Toxicol. 2022;164:113008. doi:10.1016/j.fct.2022.113008
83. Liu J, Wang J, Xu J, et al. Complete investigations revealed constant pathophysiological alterations after vaccination with COVID-19 vaccines. Cell Discov. 2021;7(1):99. doi:10.1038/s41421-021-00329-3
84. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna Okay. Kind I interferons act straight on CD8 T cells to permit clonal enlargement and reminiscence formation in response to viral an infection. J Exp Med. 2005;202(5):637–650. doi:10.1084/jem.20050821
85. Desai HD, Sharma Okay, Shah A, et al. Can SARS-CoV-2 vaccine improve the chance of reactivation of Varicella zoster? A scientific assessment. J Cosmet Dermatol. 2021;20(11):3350–3361. doi:10.1111/jocd.14521
86. Etaee F, Naguib T, Daveluy S. Herpes zoster dermatitis in a COVID-19 vaccinated wholesome man after 1 dose of varicella vaccine. JAAD Case Rep. 2022;22:102–103. doi:10.1016/j.jdcr.2021.12.043
87. Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Lengthy-term efficacy and security of risankizumab for average to extreme psoriasis: a 2-year real-life retrospective examine. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
88. Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis quickly and efficiently handled with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
89. Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug security analysis of tildrakizumab for psoriasis: a assessment of the present information. Knowledgeable Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
90. Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Fast enchancment in pruritus in atopic dermatitis sufferers handled with upadacitinib: a real-life expertise. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. doi:10.1111/jdv.18137
91. Picone V, Martora F, Fabbrocini G, Marano L. “Covid arm”: irregular aspect impact after Moderna COVID-19 vaccine. Dermatol Ther. 2022;35(1):e15197. doi:10.1111/dth.15197
92. Picone V, Fabbrocini G, Martora L, Martora F. A case of new-onset lichen planus after COVID-19 vaccination. Dermatol Ther. 2022;12(3):801–805. doi:10.1007/s13555-022-00689-y
93. Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic strategy to psoriasis sufferers with comorbidities: the position of investigational medication. Knowledgeable Opin Investig Medicine. 2023;1–16. doi:10.1080/13543784.2023.2219387
94. Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalised medication in psoriasis. Knowledgeable Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
